Literature DB >> 34086664

The GRADE approach, Part 2: Evidence to decision frameworksoutlining decision-making in health.

Carlos Quilodrán1, Matías Kirmayr2, Bárbara Valente3, Javier Pérez-Bracchiglione4, Luis Garegnani5, Juan Víctor Ariel Franco6.   

Abstract

The GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology provides a framework for assessing the certainty of the evidence and making recommendations. The Evidence to Decision Framework (EtD) is a transparent and structured system for formulating health recommendations. Once the problem is identified and the certainty of the evidence is assessed, EtD provides several criteria for formulating a recommendation. These criteria include the trade-off between benefits and harms, patients values and preferences, acceptability, feasibility, resource use, and impact on equity. The resulting recommendations may differ in strength (strong or weak) and direction (for or against). The process is transparent, allowing other users to adjust the framework of recommendations by modifying the criteria to fit the desired context through an adaptation-adoption process. Given the extensive information available on EtD and the GRADE methodology in general, this narrative review seeks to explain the main concepts involved in decision-making in health by using simplified and friendly descriptions, accompanied by practical examples, thus facilitating its understanding by inexperienced readers.

Entities:  

Keywords:  health equity; practice guideline; GRADE approach

Year:  2021        PMID: 34086664     DOI: 10.5867/medwave.2021.04.8182

Source DB:  PubMed          Journal:  Medwave        ISSN: 0717-6384


  1 in total

1.  Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement: A systematic review and meta-analysis.

Authors:  Leonel Fabrizio Trivisonno; Nadia Sgarbossa; Gustavo Ariel Alvez; Cecilia Fieiras; Camila Micaela Escobar Liquitay; Jae Hung Jung; Juan Víctor Ariel Franco
Journal:  Investig Clin Urol       Date:  2021-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.